Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

283 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.
Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M, Davies G, Khoo S, Fätkenheuer G, Youle M, Rockstroh J, Brockmeyer NH, Johnson MA, Owen A, Back DJ; German Competence Network for HIV/AIDS. Schipani A, et al. Among authors: youle m. J Antimicrob Chemother. 2011 Jun;66(6):1332-9. doi: 10.1093/jac/dkr087. Epub 2011 Mar 25. J Antimicrob Chemother. 2011. PMID: 21441248 Free PMC article.
Is interruption of HIV therapy always harmful?
Youle M. Youle M. J Antimicrob Chemother. 2000 Feb;45(2):137-8. doi: 10.1093/jac/45.2.137. J Antimicrob Chemother. 2000. PMID: 10660493 No abstract available.
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
Veldkamp AI, Harris M, Montaner JS, Moyle G, Gazzard B, Youle M, Johnson M, Kwakkelstein MO, Carlier H, van Leeuwen R, Beijnen JH, Lange JM, Reiss P, Hoetelmans RM. Veldkamp AI, et al. Among authors: youle m. J Infect Dis. 2001 Jul 1;184(1):37-42. doi: 10.1086/320998. Epub 2001 May 30. J Infect Dis. 2001. PMID: 11398107 Clinical Trial.
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
Phillips AN, Staszewski S, Lampe F, Youle MS, Klauke S, Bickel M, Sabin CA, Doerr HW, Johnson MA, Loveday C, Miller V; Royal Free Centre for HIV Medicine; Goethe Universität Clinic Cohort. Phillips AN, et al. Among authors: youle ms. J Infect Dis. 2002 Oct 15;186(8):1086-91. doi: 10.1086/343801. Epub 2002 Sep 30. J Infect Dis. 2002. PMID: 12355358 Free article.
283 results